AlphaCore Capital’s Revolution Medicines RVMD Stock Holding History

AlphaCore Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$361K	Buy	+1,759	New	+$349K	0.01%	991

Other funds holding RVMD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

AlphaCore Capital's RVMD Position: Q3 2026 in Review

AlphaCore Capital opened a new position in Revolution Medicines (RVMD) in Q3 2026: 1,759 shares worth $361K. The stake represents 0.01% of the portfolio and ranks #991 among its holdings.

329 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

AlphaCore Capital held 1,759 shares of Revolution Medicines worth $361K as of Q3 2026.
Revolution Medicines was a new AlphaCore Capital position in Q3 2026.
Revolution Medicines made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #991 holding.
329 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.